Summary
3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is an increasingly popular recreational drug in the US, Western Europe and Australia. In animals, including nonhuman primates, MDMA is known to damage brain serotonin (5-hydroxytryptamine; 5-HT) neurons. It is not known whether MDMA damages serotonin neurons in the human brain but there is some indication that it may. Although the large majority of individuals who have used MDMA recreationally do not develop acute complications, as the popularity of MDMA has increased, so have reports of adverse nonpsychiatric and psychiatric consequences associated with use of the drug. Further, since manifestations of MDMA-induced serotonin injury might only become apparent with age, or under periods of stress, it is possible that some individuals with no apparent abnormalities might develop complications over time.
Similar content being viewed by others
References
Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman R, Willette R, editors. The psychopharmacology of hallucinogens. New York: Pergamon Press, 1978: 74–83
Greer G. Using MDMA in psychotherapy. Advances 1985; 2(2): 57
Greer G, Strassman RJ. Information on ecstasy [letter]. Am J Psychiatry 1985; 142: 1391
Lawn JC. Schedules of controlled substances; temporary placement of 3,4-methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1–7
Ricaurte G, Bryan G, Strauss L, et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986–8
Abbot A, Concar D. A trip into the unknown. New Sci 1992; 29: 30–4
Randall T. (1992) Ecstasy-fueled ‘rave’ parties become dances of death for English youths. JAMA 1992; 268(12): 1505–6
Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1–7
Commins DL, Vosmer G, Virus R, et al. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338–45
O’Hearn EG, Battaglia G, De Souza, et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence. J Neurosci 1988: 8: 2788–803
Battaglia G, Yeh SY, O’Hearn E, et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetinelabelled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242(3): 911–6
Stone DM, Stahl DS, Hanson GL, et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41–8
Slikker W, Ali SF, Scallet C, et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988; 94: 448–57
Slikker Jr W, Holson RR, Ali SF, et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 1989; 10(3): 529–49
Ricaurte GA, Forno LS, Wilson MA, et al. (+)3,4-methylenedioxymethamphetamine (MDMA) selectively damaged central serotonergic neurons in non human primates. JAMA 1988; 260(1): 51–5
Insel T, Battaglia G, Johannessen J, et al. 3,4-methylenedioxymethamphetamine (‘Ecstasy’) selectively destroys brain serotonin terminals in rhesus monkeys. J Pharm Exp Ther 1989; 249(3): 713–20
Molliver ME, Berger UV, Mamounas LA, et al. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 1990; 600: 640–64
Wilson MA, Ricaurte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to MDMA. Neuroscience 1989; 28: 121–37
Ricaurte GA, Katz JL, Martello MB. Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Ther 1992; 261(2): 616–22
Ricaurte GA, DeLanney LE, Irwin I, et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446: 165–8
McCann UD, Ricaurte GA. Strategies for detecting partial monoamine depletions in humans. Natl Inst Drug Abuse Res Monogr Ser 1993; 136: 35–52
McCann UD, Ridenour A, Shaham Y, et al. Brain serotonergic neurotoxicity after MDMA (‘ecstasy’): a controlled study in humans. Neuropsychopharmacology 1994; 10: 129–38
Seymour RB. MDMA. San Francisco: Haight Ashbury Publications, 1986
Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335–40
Greer G, Tolbert P. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319–27
Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1(4): 273–7
Leister MB, Grob CS, Bravo GL, et al. Phenomenology and sequelae of 3,4-Methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180: 345–52
Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experiences with the drug. Br J Addict 1992; 87: 1161–72
O’Neill D, Dart J. Methylenedioxymethamphetamine (‘Ecstasy’) associated keratopathy. Eye 1993; 7: 805–6
Bryden AA, Rothwell PJN, O’Reilly PH. Urinary retention with misuse of ‘Ecstasy’ [letter]. BMJ 1995; 310: 504
Levine AJ, Drew S, Rees GM. ‘Ecstasy’ induced pneumomediastinum. J R Soc Med 1993: 86: 232–3
Rittoo D, Rittoo DB, Rittoo D. Misuse of ecstasy [letter]. BMJ 1992: 305: 309
Satchell SC, Connaughton M. Inappropriate hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. BMJ 1994; 51(9): 495
Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking ‘ecstasy’. BMJ 1993; 27: 1399
Russell ARB, Schwartz RH, Dawling S. Accidental ingestion of ‘ecstasy’ (3,4-methylenedioxymethamphetamine). Arch Dis Child 1992; 67: 1114–5
Dowling GP, McDonough ET, Bost RO. ‘Eve’ and ‘ecstasy’: a report of five deaths associated with the use of MDA and MDMA. JAMA 1987; 257(12): 1615–7
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’). Lancet 1992; 340: 384–7
Suarez RV, Riemersma R. ‘Ecstasy’ and sudden cardiac death. Am J Forensic Med Path 1988; 9(4): 339–41
Gledhill JA, Moore DF, Bell D, et al. Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 1993; 56(9): 1036–7
Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of ‘ecstasy’. Arch Emerg Med 1993; 10: 372–4
Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 1993; 69: 874–5
Selmi F, Davies KG, Sharma RR, et al. Intracerebral hemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. Br J Neurosurg 1995; 9: 93–6
Harries DP, De Silva R. ‘Ecstasy’ and intracerebral haemorrhage [letter]. Scott Med 1992: 37(5): 476
Hanyu S, Ikeguchi K, Imai H, et al. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine (‘ecstasy’) abuse [letter]. Eur Neurol 1995; 35: 173
Rothwell PM, Grant R. Cerebral venous sinus thrombosis induced by ‘ecstasy’ [letter]. J Neurol Neurosur Psychiatry 1993; 56: 1035–9
Squier MV, Jalloh S, Hilton-Jones D, et al. Death after ecstasy ingestion: neuropathological findings [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 756
Brown C, Osterloh J. Multiple complications from recreational ingestion of MDMA (‘Ecstasy’). JAMA 1987; 258: 780–1
Chadwick IS, Linsley A, Freemont AJ, et al. Ecstasy, 3–4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia [letter]. J R Soc Med 1991; 84: 371
Campkin NTA, Davies UM. Another death from ecstasy [letter]. J R Soc Med 1992; 85: 61
Screaton GR, Cairns HS, Sarner M, et al. Hyperpyrexia and rhabdomyolysis after MDMA (‘ecstasy’) abuse [letter]. Lancet 1992; 339(8794): 677–8
Henry J. Ecstasy and the dance of death. BMJ 1992; 305: 5–6
Barrett PJ, Taylor GT. ‘Ecstasy ‘ingestion: a case report of severe complications. J R Soc Med 1993; 86: 233–4
Padkin A. Treating MDMA (‘Ecstasy’) [letter]. Anesthesia 1994; 49(3): 259
Wake D. Ecstasy overdose: a case study. Intens Crit Care Nurs 1995; 11(1): 6–9
Walsh T, Carmichael R, Chestnut R. A hyperthermic reaction to ‘ecstasy’ [letter]. Br J Hosp Med 1994; 51(9): 476
Roberts L, Wright H. Survival following intentional massive overdose of ‘ecstasy‘. J Accid Emerg Med 1993; 11: 53–4
Lehmann ED, Thorn CH, Croft DN. Delayed severe rhabdomyolysis after taking ecstasy [letter]. Postgrad Med J 1995; 71: 186–7
Whitaker-Azmitia PM, Aronson TA. ‘Ecstasy’ (MDMA)-induced pain [letter]. Am J Psychiatry 1989; 146(1): 119
McCann UD, Ricaurte GA. MDMA (‘ecstasy’) and panic disorder: induction by a single dose. Biol Psychiatry 1992; 32: 950–3
Pallanti S, Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32: 91–5
Cox DE. ‘Rave’ to the grave. Forensic Sci Int 1993; 60: 5–6
Creighton FJ, Black DL, Hyde CE. ‘Ecstasy’ psychosis and flashbacks. Br J Psychiatry 1991; 159: 713–5
Williams H, Meagher D, Galligan P. MDMA (‘ecstasy’): a case of possible drug-induced psychosis. Irish J Med Sci 1993; 162(2): 43–4
Cadier M, Clarke J. Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burn 1993; 19(3): 239–40
Hooft PJ, Van de Voorde HP. Reckless behaviour related to the use of 3,4 methylenedioxymethamphetamine (ecstasy): apropos of fatal accident during car-surfing. Int J Legal Med 1994; 106: 328–9
Schifano F. Dangerous driving and MDMA (ecstasy) abuse. J Serotonin Res 1995; 1: 53–7
Duxbury AJ. Ecstasy —dental implications [letter]. Br Dent J 1993; 175(1): 38
Smilkstein M, Smolinske SC, Rumack BH. A case MAO inhibitor/ MDMA: agony after ecstasy. Clin Toxicol 1987; 25: 149–59
Marsh J, Abboudi Z, Gibson F, et al. Aplastic anaemic following exposure to methylenedioxymethamphetamine (‘Ecstasy’). Br J Haematol 1994; 88: 281–5
Shearman JD, Satsangi J, Chapman RWG, et al. Misuse of ecstasy [letter]. BMJ 1992: 305: 309
Ijzermans JNM, Tilanus HW, De Man RA et al. Ecstasy and liver transplantation [letter]. Ann Med Interne (Paris) 1993; 144(8): 568
Oranje WA, von Pol P, van der Wurff A, et al. XTC-induced hepatitis. Neth J Med 1994; 44: 56–9
Dykhuizen RS, Brunt PW, Atkinson P, et al. Ecstasy induced hepatitis mimicking viral hepatitis. Gut 1995; 36(6): 939–41
Series H, Boeles S, Dorkins E, et al. Psychiatric complications of ‘ecstasy’ use. J Psychopharmacol 1994; 8(1): 60–1
Schifano F, Magni G. MDMA (‘ecstasy’) abuse: psychopathological features and craving for chocolate —a case series. Soc Biol Psychiatry 1994; 36: 763–7
Mcguire PK, Cope H, Fahy T. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘ecstasy’). Br J Psychiatry 1994; 165(.3): 391–5
McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA (‘ecstasy’). BMJ 1991; 302: 607
Schifano F. Chronic atypical psychosis associated with MDMA (‘ecstasy’) abuse [letter]. Lancet 1991; 338: 1335
Wodarz N, Boning J. ‘Ecstasy’ induziertes psychotisches Depersonalisationssyndrom. Nervenarzt 1993; 64: 478–80
McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine (‘ecstasy’) in recreational users. J Clin Psychopharmacol 1991; 11: 302–5
Benazzi F, Mazzoli M. Psychiatric illness associated with ‘ecstasy’ [letter]. Lancet 1991; 338: 1520
O’Callahan J, Miller D. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 741–51
Miller DB, O’Callaghan JP. Environment-, drug-, and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 752–60
Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992; 648: 371–82
Ricaurte GA, Finnegan KT, Irwin I, et al. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600: 699–710
Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the CSF of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Res Comm Substance Abuse 1987; 8: 125–38
Ricaurte GA, Delanney LE, Wiener SG, et al. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988; 474: 359–63
Allen RP, McCann, UD, Ricaurte GA. Persistent effects of (+) 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on human sleep. Sleep 1993; 16(6): 560–4
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCann, U.D., Slate, S.O. & Ricaurte, G.A. Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Drug-Safety 15, 107–115 (1996). https://doi.org/10.2165/00002018-199615020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199615020-00003